Search results (1320)
« Back to PublicationsA phase II study of PTK787 in metastatic melanoma patients
Corrie P. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Khan OA. et al, (2008), Br J Cancer, 98, 1614 - 1618
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study.
Dummer R. et al, (2008), J Clin Oncol, 26
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
Dummer R. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
Inhibition of O-6-methylguanine DNA methyltransferase (MGMT) in solid tumors by lomeguatrib
Sabharwal A. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)
Fiore F. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC).
Fiore F. et al, (2008), J Clin Oncol, 26
Preliminary results of a Cancer Research UK phase I trial combining the dinitrobenzamide prodrug CB1954 (tretazicar) and the NQO2 substrate EP-0152R (caricotamide)
Sarker D. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
The effect of food on the single dose pharmacokinetics of cediranib
Jayson GC. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
The effect of food on the single dose pharmacokinetics of cediranib.
Jayson GC. et al, (2008), J Clin Oncol, 26
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
Mead AJ. et al, (2008), Br J Haematol, 141, 454 - 460
Automated enumeration and characterization of circulating melanoma cells in blood
Rao C. et al, (2008), CANCER RESEARCH, 68
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Blagden SP. et al, (2008), Br J Cancer, 98, 894 - 899
Pharmacotherapy of anemia in cancer patients.
Littlewood T. and Collins G., (2008), Expert Rev Clin Pharmacol, 1, 307 - 317
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
Hauschild A. et al, (2008), Cancer, 112, 982 - 994
Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells.
Rafii DC. et al, (2008), Arterioscler Thromb Vasc Biol, 28, 217 - 222
A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors
Blagden S. et al, (2008), EJC SUPPLEMENTS, 6, 135 - 136
Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer
Blagden S. et al, (2008), EJC SUPPLEMENTS, 6, 135 - 135
Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease [Letter]
Mead AJ. et al, (2008), Blood, 112, 444 - 445
Patterns of relapse in patients treated with surgery followed by platinum based chemotherapy for advanced epithelial ovarian cancer
Tuthill MH. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26